Use of antineoplastic agents in patients with cancer who have HIV/AIDS
- 30 September 2011
- journal article
- review article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 12 (9), 905-912
- https://doi.org/10.1016/s1470-2045(11)70056-0
Abstract
No abstract availableKeywords
This publication has 111 references indexed in Scilit:
- Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United StatesCancer, 2010
- Causes of Death in HIV‐1–Infected Patients Treated with Antiretroviral Therapy, 1996–2006: Collaborative Analysis of 13 HIV Cohort StudiesClinical Infectious Diseases, 2010
- Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV‐infected patientsBritish Journal of Clinical Pharmacology, 2009
- Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlookCurrent Opinion in Oncology, 2009
- Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with ZidovudineDrug Metabolism and Disposition, 2009
- Advances in Cancer TherapeuticsClinical Pharmacology & Therapeutics, 2009
- Pharmacokinetic Considerations for New Targeted TherapiesClinical Pharmacology & Therapeutics, 2008
- Maraviroc:in vitroassessment of drug-drug interaction potentialBritish Journal of Clinical Pharmacology, 2008
- IntroductionBritish Journal of Clinical Pharmacology, 2008
- Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteersBritish Journal of Clinical Pharmacology, 2008